Pfizer has secured a $10 billion deal to acquire Metsera, a fast-rising biotech company specializing in obesity and metabolic-disease treatments, after an intense bidding war with Danish pharmaceutical giant Novo Nordisk. The acquisition marks Pfizer’s most aggressive push yet to regain footing in a market it once dominated but has struggled to stabilize since the COVID-19 vaccine boom faded.
Metsera, a privately held U.S. firm backed by venture investors including Flagship Pioneering, has been developing a new class of weight-management and metabolic-regulation drugs that could challenge the blockbuster GLP-1 medications from Novo Nordisk and Eli Lilly. Pfizer’s victory signals its determination to reclaim relevance in a pharmaceutical sector that has become obsessed with metabolic innovation.
The deal comes as Pfizer faces slowing revenues and investor frustration. After record-breaking profits in 2021 and 2022 from its COVID-19 vaccine and antiviral pill, the company’s earnings have collapsed by more than 60 percent. Analysts say Pfizer desperately needs new growth drivers—and the obesity-drug market, now estimated to exceed $100 billion by the early 2030s, offers one of the most promising avenues.
Novo Nordisk, whose drugs Wegovy and Ozempic have reshaped the global weight-loss landscape, reportedly matched Pfizer’s initial bid before bowing out late Friday. Pfizer sweetened its offer with a mix of cash and stock incentives, edging out Novo by roughly $1 billion. The final price values Metsera at about $10 billion, making it one of the largest biotech takeovers of 2025.
Pfizer’s interest in the obesity-drug race isn’t new. The company previously pursued its own oral GLP-1 candidate, danuglipron, but shelved it last year due to side-effect concerns. Acquiring Metsera gives Pfizer an immediate pipeline of mid- and late-stage obesity treatments without restarting from scratch—a move many investors see as strategically essential.
If successful, the acquisition could transform Pfizer from a fading pandemic-era giant into a major player in metabolic health. But it’s also a gamble. Analysts warn that overpaying for early-stage biotech firms can backfire if their therapies fail clinical trials or face safety issues. Pfizer’s management insists that Metsera’s data are strong and that its therapies could begin Phase III testing as early as 2026.
The acquisition also underscores a broader shift in Big Pharma’s focus. Once dominated by oncology and immunology, the industry is now pivoting toward obesity, metabolic disease, and longevity science—themes increasingly linked with both public-health demand and investor enthusiasm. Goldman Sachs recently projected that obesity treatments could rival the cholesterol-drug boom of the early 2000s in scale and profitability.
For Pfizer, the $10 billion bet on Metsera is not just about chasing a trend—it’s about survival. With revenues from its COVID portfolio evaporating, the company needs new blockbusters to restore shareholder confidence and maintain its dividend. Whether Metsera’s science can deliver that remains to be seen, but for now, Wall Street has its eyes squarely on Pfizer’s bold new direction.
